EUVIMEDEUVIMED entdecken
Randomisierte kontrollierte StudieOpen Access · CC BY-NC-ND 4.0

A randomized trial of early cardiotoxicity in breast cancer patients receiving postoperative IMRT with or without serial cardiac dose constraints

Lu Cao iD, Dan Ou, Wei-Xiang Qi, Cheng Xu, Ming Ye, Yue-Hua Fang, Mei Shi, Xiao-Bo Huang, Qing Lin, Tong Liu iD, Gang Cai, Rong Cai und 6 weitere

International Journal of Cancer · 2025

DOI: 10.1002/ijc.35245 ↗

Kurz gefasst

Randomisierte kontrollierte Studie in der Zeitschrift International Journal of Cancer, 2025. Verfasst von Lu Cao und 17 weiteren Autor:innen. Beteiligte Einrichtung: Department of Radiation Oncology, Ruijin Hospital, Shanghai Jiaotong University School of Medicine, Shanghai, China. Hauptthemen laut MEDLINE: Breast Neoplasms, Radiotherapy, Intensity-Modulated, Cardiotoxicity, Heart. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 48 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: Clinical Research Plan of Shanghai Hospital Development Center, National Natural Science Foundation of China, National Key Research and Development Program of China.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Optimal cardiac dose constraints in breast cancer (BC) patients undergoing postoperative intensity‐modulated radiation therapy (IMRT) are unclear, although as low as possible is recommended. This trial proposes serial cardiac dose constraint to optimize cardiac safety. Postoperative BC patients eligible for anthracycline/taxanes‐based chemotherapy or HER2‐targeted therapy were randomized to cardiac safety arm with prespecified mean heart dose (MHD) (≤6 Gy), V30 (≤20%), and V10 (≤50%) constraints, or to a control arm with in‐house protocol (mainly MHD ≤8 Gy). The primary endpoint was cumulative incidence of newly onset cardiac events within 1‐year post‐RT. An exploratory analysis examined the relationship between whole heart dose metrics and those of substructures. Of 199 participants, 93 were in the cardiac safety and 106 in the control arm. The cardiac safety group showed lower MHD, V10, and V30. The 1‐year cardiac event incidence was slightly lower in the cardiac safety group (19.4%) compared to controls (24.9%). The LVEF and diastolic dysfunction rates were 0% and 5.4% in the study arm, and 1.9% and 8.8% in the control arm, respectively. The LAD, LV, and RV received the highest doses for left‐sided patients. For right‐sided patients, RA, RCA, and RV were most irradiated. The MHD, V10, and Dmax of heart significantly correlated with all substructure doses in either laterality. Our study supports the early cardiac safety profile using IMRT in BC patients receiving cardiac‐toxic systemic therapy, with serial cardiac dose constraints. Combined constraints on MHD and dose‐volume parameters are representative of the cardiac substructure dose.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Breast NeoplasmsRadiotherapy, Intensity-ModulatedCardiotoxicityHeartHumansFemaleMiddle AgedAdultAgedRadiotherapy DosageIncidence

Stichwörter der Autor:innen

IMRTbreast cancercardiac dose constraintscardiac substructuresearly cardiac toxicity

Autor:innen und Institutionen

  • Department of Radiation Oncology, Ruijin Hospital, Shanghai Jiaotong University School of Medicine, Shanghai, China.
  • Shanghai Key Laboratory of Proton-therapy, Shanghai, China.
  • Department of Radiation Oncology, Renji Hospital, Shanghai Jiaotong University School of Medicine, Shanghai, China.
  • Department of Cardiology, Ruijin Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China.
  • Department of Radiation Oncology, Xijing Hospital, Air Force Medical University, Xi'an, China.
  • Department of Radiation Oncology, Sun Yat-Sen Memorial Hospital, Sun Yat-Sen University, Guangzhou, China.

ORCID-Profile: Lu Cao, Tong Liu, Jia-Yi Chen

Förderung

  • Clinical Research Plan of Shanghai Hospital Development Center
  • National Natural Science Foundation of China
  • National Key Research and Development Program of China
  • Shanghai Science and Technology Innovation Action Plan
  • Clinical Research of Shanghai Municipal Health Commission
  • Shanghai Hospital Development Center Foundation

Zitieren

APA

Cao, L., Ou, D., Qi, W. X., Xu, C., Ye, M., Fang, Y. H., Shi, M., Huang, X. B., Lin, Q., Liu, T., Cai, G., Cai, R., Chen, M., Zhang, Y. B., Su, X. X., Qian, X. F., Shen, K. W., & Chen, J. Y. (2025). A randomized trial of early cardiotoxicity in breast cancer patients receiving postoperative IMRT with or without serial cardiac dose constraints. International Journal of Cancer. https://doi.org/10.1002/ijc.35245

Vancouver

Cao L, Ou D, Qi WX, Xu C, Ye M, Fang YH, et al. A randomized trial of early cardiotoxicity in breast cancer patients receiving postoperative IMRT with or without serial cardiac dose constraints. International Journal of Cancer. 2025. doi:10.1002/ijc.35245

BibTeX
@article{Cao2025,
  author = {Cao, Lu and Ou, Dan and Qi, Wei-Xiang and Xu, Cheng and Ye, Ming and Fang, Yue-Hua and Shi, Mei and Huang, Xiao-Bo and Lin, Qing and Liu, Tong and Cai, Gang and Cai, Rong and Chen, Mei and Zhang, Yi-Bin and Su, Xiu-Xiu and Qian, Xiao-Fang and Shen, Kun-Wei and Chen, Jia-Yi},
  title = {A randomized trial of early cardiotoxicity in breast cancer patients receiving postoperative IMRT with or without serial cardiac dose constraints},
  journal = {International Journal of Cancer},
  year = {2025},
  doi = {10.1002/ijc.35245}
}
Kostenlos starten →